Clinician guide

Hypertension

A practical primary care reference.

This clinician mode is designed for quick orientation and deeper review. It preserves guideline uncertainty and clinical judgment while keeping traditional medicine and lifestyle medicine together.

Patient mode Clinician mode

Key takeaways

Confirm diagnosis with proper measurement and out-of-office blood pressure when appropriate.

Assess global cardiovascular risk, comorbidities, target organ damage, secondary causes, medications, substances, and social barriers.

Lifestyle medicine is core hypertension care, not an optional add-on.

Targets require attention to risk, guideline differences, special populations, frailty, pregnancy, adverse effects, and patient context.

Home blood pressure monitoring and follow-up structure are central to durable control.

Visual overview

A primary care pathway from diagnosis to durable control.

Confirm

Measure correctly and use HBPM or ABPM when appropriate.

Risk

Assess CVD risk, target organ damage, comorbidities, and context.

Treat

Combine lifestyle medicine and pharmacotherapy according to risk.

Revise

Monitor response, labs, adverse effects, adherence, and barriers.

Clinician reference

Structured for use.

A practical reference for diagnosis, evaluation, management, monitoring, special populations, patient communication, and areas where clinical judgment remains necessary.

Blood pressure categories for hypertension diagnosis.
Category	Systolic	Diastolic
Normal BP	<120 mmHg	and <80 mmHg
Elevated BP	120-129 mmHg	and <80 mmHg
Stage 1 hypertension	130-139 mmHg	or 80-89 mmHg
Stage 2 hypertension	≥140 mmHg	or ≥90 mmHg

Clinical summary+

Hypertension is the most common chronic condition in primary care and a leading modifiable risk factor for cardiovascular disease, stroke, heart failure, chronic kidney disease, and premature death.

Management requires accurate diagnosis, out-of-office confirmation when appropriate, cardiovascular risk assessment, evaluation for target organ damage and secondary causes when indicated, lifestyle medicine, pharmacotherapy when appropriate, monitoring, and longitudinal follow-up.

Physiology and pathophysiology+

Blood pressure is determined by cardiac output and systemic vascular resistance. Chronic regulation depends heavily on renal sodium and water handling, with important contributions from the RAAS, sympathetic nervous system, endothelial function, natriuretic peptides, and circadian BP rhythm.

RAAS and SNS

RAAS overactivation promotes vasoconstriction, aldosterone-mediated sodium retention, sympathetic activation, oxidative stress, inflammation, and vascular remodeling. Sympathetic hyperactivity increases cardiac output, vascular resistance, and renal sodium reabsorption.

Kidney and sodium balance

Impaired pressure-natriuresis shifts the kidney toward maintaining sodium balance only at higher blood pressure levels, supporting chronic hypertension.

Endothelium and vessels

Reduced nitric oxide bioavailability, increased reactive oxygen species, endothelin activity, inflammation, and arterial stiffness contribute to vasoconstriction and higher systolic BP.

Metabolic and genetic factors

Insulin resistance, obesity, hyperinsulinemia, and many small-effect genetic loci contribute to interindividual blood pressure variation.

Epidemiology and disparities+

Hypertension affects approximately 45% of U.S. adults by current thresholds and approximately 1.71 billion adults worldwide. Prevalence increases sharply with age and control rates remain low.

U.S. prevalence

Approximately 116–120 million U.S. adults have hypertension.

Global burden

1.71 billion adults worldwide had hypertension in 2020.

Control

Only about 23–24% of U.S. adults with hypertension achieve BP 130/80 mmHg.

Black adults have the highest prevalence among major U.S. racial and ethnic groups, develop hypertension earlier, and experience higher rates of stroke, heart failure, and ESRD. These differences should be approached through clinical care, structural awareness, access, affordability, and trust.

Natural history, complications, and prognosis+

Without intervention, blood pressure often rises gradually over years to decades as vascular remodeling, arterial stiffness, and renal functional changes progress. Risk is continuous and graded, rather than confined to a single threshold.

Target organ damage

Hypertension can lead to left ventricular hypertrophy, ischemic heart disease, heart failure, stroke, retinopathy, CKD, albuminuria, vascular disease, cognitive impairment, and sexual dysfunction.

Earlier onset

Hypertension before age 45 confers higher long-term cardiovascular and mortality risk, even among treated patients.

Older adults

Isolated systolic hypertension becomes more common with age because of progressive arterial stiffening.

Treatment effect

A 10 mmHg systolic BP reduction lowers cardiovascular event risk by approximately 20–30%.

Prognosis depends on BP severity and duration, overall cardiovascular risk, comorbidities, target organ damage, adherence, treatment response, and whether lifestyle and social barriers can be addressed.

Diagnosis+

Diagnosis requires accurate office measurement and confirmation with out-of-office measurements when appropriate. Office diagnosis should be based on elevated blood pressure on at least two occasions.

Out-of-office measure	Threshold
HBPM average	≥130/80 mmHg
ABPM daytime average	≥130/80 mmHg
ABPM nighttime average	≥110/65 mmHg
ABPM 24-hour average	≥125/75 mmHg

Pregnancy uses pregnancy-specific criteria and management.

Evaluation+

Initial evaluation should confirm the diagnosis, assess baseline cardiovascular risk, identify target organ damage, screen for secondary causes when indicated, identify comorbidities and cardiovascular risk factors, assess lifestyle factors, and identify social, financial, behavioral, and access barriers.

History

BP history, treatment response, adherence, CVD risk factors, target organ symptoms, secondary clues, medications, substances, lifestyle, psychosocial factors, and family history.

Routine tests

CBC, sodium, potassium, calcium, creatinine/eGFR, lipid profile, fasting glucose or HbA1c, TSH, urinalysis, urine albumin-to-creatinine ratio or protein-to-creatinine ratio, and ECG.

Differential diagnosis+

primary hypertension
secondary hypertension
white coat hypertension
masked hypertension
measurement artifact
acute pain or anxiety causing transient elevation
medication-induced hypertension
substance-induced hypertension
pseudohypertension in selected older adults

Management+

Management combines lifestyle medicine and pharmacotherapy based on blood pressure level, cardiovascular risk, comorbidities, safety, patient context, and clinical judgment.

Clinical situation	Recommendation
BP ≥140/90 mmHg	Initiate pharmacotherapy for all adults, in addition to lifestyle intervention.
BP ≥130/80 mmHg with high CVD risk	Pharmacotherapy recommended.
BP ≥130/80 mmHg with lower CVD risk	Pharmacotherapy if BP remains elevated after 3-6 months of lifestyle modification.

Medications+

Pharmacotherapy should be chosen according to blood pressure level, cardiovascular risk, comorbidities, safety, adherence, cost, and patient context. The Treatment section below summarizes how medication fits within the Contrada two-pillar approach.

Lifestyle medicine+

Lifestyle modification is recommended for all patients with elevated blood pressure or hypertension, whether or not medication is used. The Treatment section below summarizes the major lifestyle domains and how they are integrated with traditional medical management.

Monitoring and follow-up+

Monitor office blood pressure, HBPM when feasible, ABPM when confirmation or complex interpretation is needed, electrolytes, creatinine/eGFR, UACR when diabetes or CKD is present, lipids, glucose, orthostatic BP when indicated, adherence, adverse effects, symptoms, lifestyle progress, and social barriers.

Reassessment is commonly needed one month after initiating or changing therapy, with monthly follow-up until goal is achieved, three-month intervals until stability is confirmed, and a maximum office interval of six months once stable and controlled on medication.

Special populations+

Pregnancy

Pregnancy requires pregnancy-specific thresholds and medication choices. Preferred agents include labetalol and extended-release nifedipine. ACE inhibitors, ARBs, direct renin inhibitors, nitroprusside, MRAs, and atenolol are listed as contraindicated.

Older adults and frailty

Targets should be individualized in clinically significant frailty, frequent falls, advanced cognitive impairment, or limited life expectancy. Orthostatic symptoms and falls risk require attention.

Diabetes

Hypertension and diabetes frequently coexist and increase cardiovascular risk. A BP target of 130/80 mmHg and preference for ACE inhibitors or ARBs, especially with albuminuria or diabetic nephropathy, should be considered in appropriate patients.

Chronic kidney disease

Hypertension is both a cause and consequence of CKD. A BP target of 130/80 mmHg and preference for ACE inhibitor or ARB in proteinuric CKD should be considered, with close potassium and creatinine monitoring.

Heart failure and stroke

BP control is essential in heart failure prevention and management. For secondary stroke prevention, a BP target of 130/80 mmHg should be considered in appropriate patients.

Patient communication+

Blood pressure is important because it affects risk over time, even when you feel well.
We should confirm the pattern before we label or treat the number.
Medication and lifestyle are not competing approaches. For many people, they work best together.
The goal is not to make you anxious about every reading. The goal is to understand the pattern and lower risk safely.
If the plan is not realistic in your daily life, we need to revise the plan.

Pearls and pitfalls+

Pearls

Accurate measurement is part of treatment, not a clerical detail.
Out-of-office BP can change diagnosis and management.
Lifestyle medicine is core hypertension care.
Resistant hypertension should be confirmed before intensification.
Social determinants can determine whether a plan is feasible.

Pitfalls

Treating one office reading as diagnostic.
Missing white coat or masked hypertension.
Escalating medication without assessing adherence, technique, or barriers.
Applying intensive targets without considering patient context.
Treating medication as a substitute for lifestyle assessment.

Guideline notes and uncertainty+

The primary guideline for this topic is the 2025 AHA/ACC/Multisociety Guideline. Related references include the 2017 ACC/AHA guideline, AAFP review, JAMA review, ADA Standards of Care for diabetes, pregnancy-related guidance, AHA scientific statements, and other evidence-based sources.

Some guidance differs by population and guideline body. The most notable tension is blood pressure target selection for lower-risk patients, where AAFP recommendations differ from ACC/AHA targets. Clinicians should verify current recommendations and apply judgment.

Evidence gaps and future directions+

Hypertension care is evidence-rich, but several areas continue to evolve. Clinicians should distinguish established practice from emerging evidence and reassess recommendations as guidelines change.

Implementation

Improving long-term control, adherence, team-based care, home monitoring workflows, affordability, and follow-up remains a central challenge.

Lifestyle medicine

The best ways to personalize and sustain nutrition, movement, sleep, stress, and social interventions require continued study.

Devices and emerging therapies

Renal denervation, endothelin receptor antagonists, aldosterone synthase inhibitors, RNA-based therapies, and other approaches require indication-specific review before routine use.

Equity and digital tools

Digital monitoring and decision-support tools may help continuity of care, but privacy, access, bias, and clinical governance must be addressed.

Treatment

Two pillars, one clinical plan.

In clinician mode, the Contrada approach keeps pharmacologic care and lifestyle medicine together. The balance is determined by blood pressure level, cardiovascular risk, comorbidities, safety, feasibility, and longitudinal follow-up.

Traditional medicine management

Confirm, risk-stratify, treat, monitor.

Diagnosis

Use accurate office technique and out-of-office confirmation when appropriate. Distinguish sustained, white coat, masked, and measurement-related elevation.

Risk and evaluation

Assess global cardiovascular risk, target organ damage, comorbidities, secondary causes when indicated, medications, substances, and barriers to care.

Pharmacotherapy

Initiate medication according to blood pressure level, cardiovascular risk, comorbidities, safety, and patient context. First-line classes include ACE inhibitors, ARBs, long-acting dihydropyridine calcium channel blockers, and thiazide or thiazide-like diuretics.

Medication selection

Selection should account for pregnancy, CKD, diabetes, heart failure, stroke history, frailty, adverse effects, kidney function, electrolytes, adherence, cost, and patient preferences.

Monitoring

Follow blood pressure response, home readings when feasible, electrolytes, creatinine/eGFR, adverse effects, adherence, and clinical status over time.

Lifestyle medicine management

Make treatment feasible in daily life.

Nutrition

Use DASH-style dietary patterns, sodium reduction, cautious potassium enrichment when appropriate, and weight management when clinically relevant.

Movement

Encourage at least 150 minutes/week of moderate aerobic activity or 75 minutes/week of vigorous activity, resistance training at least two days/week, and reduced sedentary time, with safety judgment before vigorous activity in very high blood pressure.

Sleep and stress

Assess sleep duration, quality, timing, insomnia, shift work, obstructive sleep apnea, chronic stress, depression, anxiety, financial strain, and discrimination.

Social and substance factors

Review food insecurity, medication affordability, transportation, health literacy, routine care access, support, alcohol, tobacco, nicotine, cannabis, stimulants, BP-raising medications, and supplements.

Secondary contributors

Screen resistant hypertension for obstructive sleep apnea when appropriate, and review BP-raising medications, supplements, and substances before intensifying therapy.

References and review

This clinician guide is derived from the hypertension Knowledge Database source documents. Full citations and source-tracking notes are maintained in the internal references file. This Academy page has been reviewed according to Contrada Academy standards for educational use.